Skip to main content

Table 6 Data from sleep questionnaires including domain scores

From: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

 

PEA

Placebo

Baseline

Week 4

Week 8

Baseline

Week 4

Week 8

Epworth Sleepiness Scale

6.5 ± 4.4

4.6 ± 3.8

4.7 ± 4.1

6.7 ± 4.1

4.8 ± 3.9

4.3 ± 4.1

PROMIS

61.5 ± 6.0

56.8 ± 6.5

55.3 ± 6.6

62.2 ± 6.5

56.5 ± 6.7

55.1 ± 9.0

SIQ Total score

45.1 ± 15.7

36.9 ± 13.1

37.1 ± 12.4

45.0 ± 12.4

37.1 ± 15.0

36.8 ± 15.1

SIQ Physiological

15.8 ± 6.0

12.2 ± 4.5

12.4 ± 4.7

16.2 ± 4.9

12.8 ± 5.7

12.6 ± 5.5

SIQ Responses to Sleep Inertia

13.8 ± 5.2

12.3 ± 4.9

11.6 ± 4.3

14.5 ± 4.6

12.0 ± 4.7

12.0 ± 5.0

SIQ Cognitive

10.5 ± 4.6

9.0 ± 3.7

8.0 ± 3.2a

9.4 ± 3.0

7.4 ± 3.6

7.8 ± 4.1

SIQ Emotional

4.9 ± 2.6

4.4 ± 2.3

4.2 ± 1.6

4.9 ± 2.3

4.5 ± 2.7

4.8 ± 2.8

SIQ Time to feel completely awake

25.9 ± 25.3

18.4 ± 21.1

14.7 ± 17.5a

23.6 ± 23.8

20.4 ± 20.4

22.4 ± 25.1

  1. N.B. Data presented as mean ± standard deviation;  asignificant difference between groups at p < 0.05; PEA  Palmitoylethanolamide, PROMIS Patient Reported Outcomes Measurement Information System, SIQ The Sleep Inertia Questionnaire